Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase

Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase

US Patent 7405205 · Granted Jul 29, 2008

Estimated economic value: $697,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Aryl imidazoles and their use as anti-cancer agents2018
2-substituted imidazo[4,5-D]phenanthroline derivatives and their use in the trea2016
2,4,5-trisubstituted imidazoles and their use as anti-microbial agents2015
Aryl imidazoles and their use as anti-cancer agents2015
Combination preparation of a biological response modifier and an anticancer agen2013
2,4,5-trisubstituted imidazoles and their use as anti-microbial agents2013
Use of interleukin 17E for the treatment of cancer2012
Use of interleukin 17E for the treatment of cancer2012
2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatm2012
2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatm2012
Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses ther2011
Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses ther2011